A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

2024-514532-24-00 Protocol 1403-0004 Human pharmacology (Phase I) - Other Ended

Start 23 Jun 2022 · End 29 Apr 2025 · Status Ended · 2 EU/EEA countries · 7 sites · Protocol 1403-0004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 33
Countries 2
Sites 7

Solid cancer tumors

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Jun 2022 → 29 Apr 2025
Decision date (initial)
2024-09-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514532-24-00
EudraCT number
2021-006565-38
ClinicalTrials.gov
NCT05372367

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid cancer tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 6 2
Spain Ended 27 5
Rest of world 0

Investigational sites

Belgium

2 sites · Ended
GasthuisZusters Antwerpen
Oncology, Oosterveldlaan 22, 2610, Antwerp
Cliniques Universitaires Saint-Luc
Oncology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe

Spain

5 sites · Ended
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2022-06-23 2024-06-28 2022-08-18 2024-06-05
Spain 2022-07-29 2022-10-17 2024-06-05

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-26 Spain Acceptable with conditions
2024-09-24
2024-09-24
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-06 Spain Acceptable with conditions
2024-09-24
2024-12-06